Randall Mark Zusman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antihypertensive Agents | 19 | 2008 | 2043 | 0.800 |
Why?
|
| Hypertension | 33 | 2018 | 8455 | 0.800 |
Why?
|
| Erectile Dysfunction | 6 | 2000 | 459 | 0.690 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 4 | 1999 | 56 | 0.680 |
Why?
|
| Phosphodiesterase Inhibitors | 4 | 2000 | 215 | 0.650 |
Why?
|
| Piperazines | 7 | 2005 | 2488 | 0.520 |
Why?
|
| Blood Pressure | 32 | 2018 | 8541 | 0.520 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 11 | 2003 | 1517 | 0.450 |
Why?
|
| Relaxation Therapy | 2 | 2018 | 178 | 0.430 |
Why?
|
| Arteriosclerosis | 3 | 2000 | 1092 | 0.390 |
Why?
|
| Propranolol | 5 | 2011 | 502 | 0.360 |
Why?
|
| Platelet Aggregation Inhibitors | 6 | 2000 | 3067 | 0.330 |
Why?
|
| Sexual Dysfunctions, Psychological | 2 | 2000 | 187 | 0.330 |
Why?
|
| Heart Rate | 12 | 2012 | 4091 | 0.320 |
Why?
|
| Nifedipine | 4 | 1999 | 226 | 0.300 |
Why?
|
| Doxazosin | 2 | 2004 | 19 | 0.290 |
Why?
|
| Acupuncture | 1 | 2006 | 90 | 0.280 |
Why?
|
| Ticlopidine | 3 | 2000 | 899 | 0.280 |
Why?
|
| Angina Pectoris | 6 | 2000 | 977 | 0.270 |
Why?
|
| Coronary Disease | 4 | 2000 | 6078 | 0.250 |
Why?
|
| Bepridil | 4 | 1993 | 12 | 0.250 |
Why?
|
| Prostaglandins | 7 | 1987 | 405 | 0.240 |
Why?
|
| Critical Pathways | 3 | 2009 | 475 | 0.240 |
Why?
|
| Proline | 3 | 1992 | 458 | 0.230 |
Why?
|
| Sulfones | 7 | 2005 | 437 | 0.230 |
Why?
|
| Renin | 10 | 1994 | 642 | 0.220 |
Why?
|
| Purines | 7 | 2005 | 593 | 0.220 |
Why?
|
| Heart | 8 | 2012 | 4462 | 0.200 |
Why?
|
| Diltiazem | 2 | 1992 | 133 | 0.180 |
Why?
|
| Prostatic Hyperplasia | 1 | 2004 | 522 | 0.180 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2000 | 174 | 0.170 |
Why?
|
| Acupuncture Therapy | 1 | 2004 | 464 | 0.170 |
Why?
|
| Ventricular Function, Left | 7 | 1999 | 3656 | 0.170 |
Why?
|
| Cardiology | 2 | 2000 | 1658 | 0.170 |
Why?
|
| Captopril | 4 | 1988 | 272 | 0.170 |
Why?
|
| Drug Interactions | 6 | 2000 | 1458 | 0.160 |
Why?
|
| Activities of Daily Living | 1 | 2008 | 2414 | 0.160 |
Why?
|
| Nitroglycerin | 5 | 1999 | 325 | 0.150 |
Why?
|
| Enzyme Inhibitors | 2 | 1999 | 3800 | 0.150 |
Why?
|
| Life Style | 1 | 2008 | 3824 | 0.140 |
Why?
|
| Angiotensin II | 6 | 1994 | 881 | 0.140 |
Why?
|
| Double-Blind Method | 13 | 2008 | 12017 | 0.140 |
Why?
|
| Oligopeptides | 4 | 1994 | 1176 | 0.130 |
Why?
|
| Vasodilator Agents | 4 | 2005 | 976 | 0.130 |
Why?
|
| Vasodilation | 1 | 1999 | 944 | 0.120 |
Why?
|
| Cardiovascular Diseases | 6 | 2009 | 15108 | 0.120 |
Why?
|
| Clinical Trials as Topic | 14 | 2004 | 7901 | 0.120 |
Why?
|
| Prostaglandins E | 4 | 1984 | 172 | 0.120 |
Why?
|
| Vascular Resistance | 6 | 1993 | 936 | 0.120 |
Why?
|
| Drug Therapy, Combination | 9 | 2006 | 6483 | 0.120 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 1999 | 923 | 0.120 |
Why?
|
| Nitric Oxide | 2 | 1999 | 2128 | 0.110 |
Why?
|
| Stress, Psychological | 1 | 2008 | 4229 | 0.110 |
Why?
|
| Exercise Test | 6 | 2012 | 2075 | 0.110 |
Why?
|
| Epoprostenol | 3 | 1985 | 254 | 0.110 |
Why?
|
| Hemodynamics | 4 | 1993 | 4197 | 0.110 |
Why?
|
| Atenolol | 1 | 1992 | 100 | 0.110 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2011 | 1239 | 0.100 |
Why?
|
| Dextroamphetamine | 1 | 2012 | 129 | 0.100 |
Why?
|
| Patient Selection | 1 | 2004 | 4214 | 0.100 |
Why?
|
| Cardiovascular System | 1 | 1999 | 827 | 0.100 |
Why?
|
| Drive | 1 | 2011 | 35 | 0.100 |
Why?
|
| Central Nervous System Stimulants | 2 | 2012 | 1148 | 0.090 |
Why?
|
| Calcium Channel Blockers | 4 | 1989 | 689 | 0.090 |
Why?
|
| Sexual Behavior | 1 | 2000 | 2050 | 0.090 |
Why?
|
| Dipeptides | 1 | 1992 | 409 | 0.090 |
Why?
|
| Diuretics | 3 | 1988 | 591 | 0.090 |
Why?
|
| Imagination | 1 | 2011 | 221 | 0.090 |
Why?
|
| Renin-Angiotensin System | 4 | 1992 | 759 | 0.090 |
Why?
|
| Radionuclide Angiography | 4 | 1993 | 23 | 0.080 |
Why?
|
| Myocardial Infarction | 2 | 2000 | 11690 | 0.080 |
Why?
|
| Coitus | 2 | 2000 | 133 | 0.080 |
Why?
|
| Humans | 66 | 2018 | 742088 | 0.080 |
Why?
|
| Kidney Medulla | 3 | 1984 | 182 | 0.080 |
Why?
|
| Bradykinin | 3 | 1987 | 214 | 0.080 |
Why?
|
| Research Design | 1 | 2004 | 5979 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 6 | 2009 | 7276 | 0.070 |
Why?
|
| Arachidonic Acids | 1 | 1987 | 299 | 0.070 |
Why?
|
| Diastole | 4 | 1993 | 791 | 0.070 |
Why?
|
| Male | 41 | 2018 | 349538 | 0.070 |
Why?
|
| Coronary Circulation | 2 | 2005 | 1572 | 0.070 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 1992 | 859 | 0.070 |
Why?
|
| Pyrrolidines | 2 | 1985 | 342 | 0.070 |
Why?
|
| Cardiac Output | 3 | 1993 | 853 | 0.070 |
Why?
|
| Amphetamines | 1 | 2006 | 148 | 0.070 |
Why?
|
| Brain Ischemia | 1 | 1999 | 3258 | 0.060 |
Why?
|
| Arginine Vasopressin | 1 | 1984 | 130 | 0.060 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2012 | 3649 | 0.060 |
Why?
|
| Myocardial Contraction | 1 | 1989 | 1585 | 0.060 |
Why?
|
| Random Allocation | 6 | 1988 | 2425 | 0.060 |
Why?
|
| Adult | 30 | 2018 | 213712 | 0.060 |
Why?
|
| Personal Satisfaction | 1 | 2008 | 634 | 0.060 |
Why?
|
| Butanones | 1 | 2003 | 27 | 0.060 |
Why?
|
| Systole | 4 | 1999 | 956 | 0.060 |
Why?
|
| Middle Aged | 27 | 2018 | 213127 | 0.060 |
Why?
|
| Fosinopril | 2 | 1992 | 8 | 0.050 |
Why?
|
| Myocardial Ischemia | 2 | 2005 | 2145 | 0.050 |
Why?
|
| Ibuprofen | 1 | 2003 | 235 | 0.050 |
Why?
|
| Uremia | 1 | 1981 | 200 | 0.050 |
Why?
|
| United States | 8 | 2009 | 69693 | 0.050 |
Why?
|
| Prazosin | 1 | 2000 | 96 | 0.050 |
Why?
|
| Aged | 15 | 2018 | 162944 | 0.050 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 1999 | 67 | 0.040 |
Why?
|
| Reference Values | 3 | 1999 | 4982 | 0.040 |
Why?
|
| Delayed-Action Preparations | 3 | 2006 | 965 | 0.040 |
Why?
|
| Blood Platelets | 2 | 2000 | 2506 | 0.040 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2011 | 4248 | 0.040 |
Why?
|
| Algorithms | 3 | 2009 | 13853 | 0.040 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 1999 | 152 | 0.040 |
Why?
|
| Biological Availability | 1 | 1999 | 396 | 0.040 |
Why?
|
| Female | 29 | 2018 | 379592 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 1 | 1999 | 379 | 0.040 |
Why?
|
| Stents | 2 | 2000 | 3276 | 0.040 |
Why?
|
| Relaxation | 1 | 2018 | 50 | 0.040 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 1999 | 187 | 0.040 |
Why?
|
| Aldosterone | 4 | 1994 | 876 | 0.040 |
Why?
|
| Risk Factors | 6 | 2000 | 72145 | 0.040 |
Why?
|
| Stroke | 1 | 2000 | 9963 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2008 | 2575 | 0.040 |
Why?
|
| Receptors, Angiotensin | 3 | 1984 | 142 | 0.040 |
Why?
|
| Risk | 2 | 1999 | 9679 | 0.040 |
Why?
|
| Angina, Unstable | 2 | 1993 | 926 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2018 | 53187 | 0.030 |
Why?
|
| Safety | 1 | 2000 | 1185 | 0.030 |
Why?
|
| Calcium | 2 | 1989 | 5753 | 0.030 |
Why?
|
| Sodium | 4 | 1983 | 1627 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2000 | 786 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1999 | 1791 | 0.030 |
Why?
|
| Paraneoplastic Endocrine Syndromes | 1 | 1974 | 31 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 1991 | 4250 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2005 | 3099 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 15530 | 0.030 |
Why?
|
| Heart Diseases | 2 | 1999 | 2789 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2004 | 8297 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2003 | 1932 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1994 | 683 | 0.030 |
Why?
|
| Heart Function Tests | 1 | 1993 | 330 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 2276 | 0.030 |
Why?
|
| Lisinopril | 1 | 1992 | 54 | 0.030 |
Why?
|
| Urine | 1 | 1994 | 370 | 0.030 |
Why?
|
| Heart Valve Diseases | 1 | 2000 | 1067 | 0.030 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 1993 | 219 | 0.030 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2000 | 1541 | 0.030 |
Why?
|
| Stroke Volume | 3 | 1993 | 4983 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 1981 | 1780 | 0.030 |
Why?
|
| Chlorthalidone | 1 | 1991 | 19 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2009 | 11695 | 0.030 |
Why?
|
| Administration, Oral | 1 | 1999 | 3913 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 1999 | 1581 | 0.020 |
Why?
|
| Supination | 1 | 1991 | 68 | 0.020 |
Why?
|
| Fibrinolytic Agents | 1 | 1981 | 2156 | 0.020 |
Why?
|
| Infusion Pumps | 1 | 1991 | 163 | 0.020 |
Why?
|
| Comorbidity | 2 | 2006 | 10372 | 0.020 |
Why?
|
| Sodium Chloride | 2 | 1987 | 625 | 0.020 |
Why?
|
| Kinins | 2 | 1979 | 22 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2008 | 62966 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 1707 | 0.020 |
Why?
|
| Galvanic Skin Response | 1 | 2011 | 349 | 0.020 |
Why?
|
| Liver Diseases | 1 | 1977 | 1252 | 0.020 |
Why?
|
| Leg | 1 | 1993 | 1110 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 2 | 1981 | 2536 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2011 | 6030 | 0.020 |
Why?
|
| Platelet Aggregation | 2 | 1981 | 800 | 0.020 |
Why?
|
| Aspirin | 1 | 1999 | 3278 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 1999 | 3611 | 0.020 |
Why?
|
| Vasoconstriction | 1 | 1989 | 596 | 0.020 |
Why?
|
| Culture Techniques | 2 | 1984 | 554 | 0.020 |
Why?
|
| Homeostasis | 2 | 1994 | 3335 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 1987 | 434 | 0.020 |
Why?
|
| Angiotensinogen | 2 | 1983 | 163 | 0.020 |
Why?
|
| Electromyography | 1 | 2011 | 1391 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1989 | 780 | 0.020 |
Why?
|
| Time Factors | 4 | 1999 | 40054 | 0.020 |
Why?
|
| Electrocardiography | 4 | 2006 | 6440 | 0.020 |
Why?
|
| Enalapril | 1 | 1987 | 327 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 1987 | 711 | 0.020 |
Why?
|
| Norepinephrine | 1 | 1987 | 909 | 0.020 |
Why?
|
| Psychotropic Drugs | 1 | 1991 | 893 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1987 | 1676 | 0.020 |
Why?
|
| Trifluoperazine | 1 | 1984 | 40 | 0.020 |
Why?
|
| Ischemia | 1 | 1993 | 1911 | 0.020 |
Why?
|
| Calcimycin | 1 | 1984 | 222 | 0.020 |
Why?
|
| Psychophysiologic Disorders | 1 | 1986 | 228 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 1984 | 326 | 0.020 |
Why?
|
| Physical Exertion | 1 | 1987 | 695 | 0.010 |
Why?
|
| Anger | 1 | 1986 | 402 | 0.010 |
Why?
|
| Verapamil | 1 | 1984 | 244 | 0.010 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 802 | 0.010 |
Why?
|
| Lipoproteins | 1 | 1988 | 876 | 0.010 |
Why?
|
| Heart Failure | 2 | 2000 | 10856 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1999 | 9941 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 1988 | 1679 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 1989 | 1310 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 2006 | 632 | 0.010 |
Why?
|
| Rabbits | 3 | 1984 | 4886 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 9410 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1987 | 3133 | 0.010 |
Why?
|
| Psychometrics | 1 | 2011 | 2999 | 0.010 |
Why?
|
| Dinoprostone | 1 | 1984 | 600 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1981 | 415 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1985 | 2027 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1987 | 1262 | 0.010 |
Why?
|
| World Health Organization | 1 | 1986 | 1317 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2000 | 57683 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 1987 | 1813 | 0.010 |
Why?
|
| Teprotide | 1 | 1979 | 28 | 0.010 |
Why?
|
| Blood Coagulation | 2 | 1987 | 1126 | 0.010 |
Why?
|
| Receptors, Cell Surface | 2 | 1980 | 2867 | 0.010 |
Why?
|
| Echocardiography | 1 | 2012 | 5097 | 0.010 |
Why?
|
| Cholesterol | 1 | 1988 | 2895 | 0.010 |
Why?
|
| Medication Adherence | 1 | 2011 | 2055 | 0.010 |
Why?
|
| Bartter Syndrome | 1 | 1979 | 24 | 0.010 |
Why?
|
| Triglycerides | 1 | 1987 | 2450 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2000 | 23320 | 0.010 |
Why?
|
| Posture | 1 | 1983 | 958 | 0.010 |
Why?
|
| Body Temperature | 1 | 1981 | 776 | 0.010 |
Why?
|
| Patient Compliance | 1 | 1988 | 2680 | 0.010 |
Why?
|
| Prostaglandins F | 1 | 1977 | 81 | 0.010 |
Why?
|
| Prostaglandins, Synthetic | 1 | 1977 | 21 | 0.010 |
Why?
|
| Prostaglandins A | 1 | 1977 | 16 | 0.010 |
Why?
|
| Quality of Life | 2 | 1989 | 12730 | 0.010 |
Why?
|
| Natriuresis | 1 | 1977 | 124 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 1977 | 193 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 1974 | 4229 | 0.010 |
Why?
|
| Diuresis | 1 | 1977 | 116 | 0.010 |
Why?
|
| Potassium | 3 | 1979 | 1336 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 1989 | 3801 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 6365 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1974 | 6347 | 0.010 |
Why?
|
| Accidents, Traffic | 1 | 2002 | 819 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 1999 | 1144 | 0.010 |
Why?
|
| Arousal | 1 | 2002 | 1165 | 0.010 |
Why?
|
| Hyperaldosteronism | 1 | 1979 | 239 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1999 | 1423 | 0.010 |
Why?
|
| Renal Artery | 1 | 1977 | 398 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2012 | 21719 | 0.010 |
Why?
|
| Adolescent | 3 | 2011 | 85649 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 1107 | 0.010 |
Why?
|
| Heparin | 1 | 1981 | 1636 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 4929 | 0.010 |
Why?
|
| Steroids | 1 | 1979 | 931 | 0.010 |
Why?
|
| Age Factors | 2 | 2006 | 18355 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2003 | 1970 | 0.010 |
Why?
|
| Catheterization | 1 | 1977 | 1468 | 0.010 |
Why?
|
| Foreign-Body Migration | 1 | 1993 | 221 | 0.010 |
Why?
|
| Equipment Failure | 1 | 1993 | 579 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 1989 | 5304 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 1973 | 683 | 0.010 |
Why?
|
| Syndrome | 1 | 1977 | 3248 | 0.010 |
Why?
|
| Aorta, Abdominal | 1 | 1993 | 645 | 0.010 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1993 | 548 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 1993 | 1095 | 0.010 |
Why?
|
| Body Weight | 2 | 1987 | 4664 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 6259 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 10943 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 39004 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1981 | 3461 | 0.010 |
Why?
|
| Acute Kidney Injury | 1 | 1981 | 1967 | 0.010 |
Why?
|
| Animals | 6 | 1987 | 168561 | 0.010 |
Why?
|
| Nephrectomy | 1 | 1974 | 1049 | 0.000 |
Why?
|
| Pacemaker, Artificial | 1 | 1993 | 817 | 0.000 |
Why?
|
| Retrospective Studies | 2 | 2011 | 77098 | 0.000 |
Why?
|
| Thallium | 1 | 1987 | 101 | 0.000 |
Why?
|
| Hostility | 1 | 1987 | 189 | 0.000 |
Why?
|
| Mental Disorders | 1 | 2006 | 6587 | 0.000 |
Why?
|
| Vagotomy | 1 | 1985 | 83 | 0.000 |
Why?
|
| Pressoreceptors | 1 | 1985 | 100 | 0.000 |
Why?
|
| Radioisotopes | 1 | 1987 | 499 | 0.000 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1985 | 231 | 0.000 |
Why?
|
| Sympathetic Nervous System | 1 | 1987 | 514 | 0.000 |
Why?
|
| Young Adult | 1 | 2011 | 56350 | 0.000 |
Why?
|
| Pepstatins | 1 | 1983 | 10 | 0.000 |
Why?
|
| Denervation | 1 | 1985 | 278 | 0.000 |
Why?
|
| Coronary Artery Bypass | 1 | 1993 | 2281 | 0.000 |
Why?
|
| Haplorhini | 1 | 1983 | 551 | 0.000 |
Why?
|
| Placebos | 1 | 1987 | 1677 | 0.000 |
Why?
|
| Emergency Service, Hospital | 1 | 2002 | 7645 | 0.000 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 1983 | 311 | 0.000 |
Why?
|
| Postoperative Complications | 2 | 1993 | 15244 | 0.000 |
Why?
|
| Phenylmethylsulfonyl Fluoride | 1 | 1980 | 6 | 0.000 |
Why?
|
| Carotid Arteries | 1 | 1985 | 952 | 0.000 |
Why?
|
| Dithiothreitol | 1 | 1980 | 101 | 0.000 |
Why?
|
| Dogs | 1 | 1985 | 3910 | 0.000 |
Why?
|
| Organ Size | 1 | 1985 | 2253 | 0.000 |
Why?
|
| Protease Inhibitors | 1 | 1983 | 790 | 0.000 |
Why?
|
| Prekallikrein | 1 | 1979 | 11 | 0.000 |
Why?
|
| Monitoring, Physiologic | 1 | 1987 | 1737 | 0.000 |
Why?
|
| Fludrocortisone | 1 | 1979 | 25 | 0.000 |
Why?
|
| Spleen | 1 | 1985 | 2359 | 0.000 |
Why?
|
| Aorta | 1 | 1985 | 2057 | 0.000 |
Why?
|
| Recombinant Proteins | 1 | 1987 | 6608 | 0.000 |
Why?
|
| Kallikreins | 1 | 1979 | 258 | 0.000 |
Why?
|
| Social Class | 1 | 1986 | 1995 | 0.000 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1979 | 648 | 0.000 |
Why?
|
| Iodine Radioisotopes | 1 | 1980 | 1030 | 0.000 |
Why?
|
| Antibodies | 1 | 1983 | 2459 | 0.000 |
Why?
|
| Coronary Angiography | 1 | 1987 | 4567 | 0.000 |
Why?
|
| Diet | 1 | 1973 | 7923 | 0.000 |
Why?
|
| Sex Factors | 1 | 1986 | 10392 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1983 | 13814 | 0.000 |
Why?
|
| Binding Sites | 1 | 1980 | 6115 | 0.000 |
Why?
|
| Depression | 1 | 1987 | 7733 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 1983 | 9274 | 0.000 |
Why?
|
| Obesity | 1 | 1986 | 12705 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1979 | 19223 | 0.000 |
Why?
|
| Child | 1 | 1979 | 77478 | 0.000 |
Why?
|